Wave Life Sciences Q3 revenue rises to $13.2 million; net loss widens to $61.9 million
Wave Life Sciences reported third quarter 2026 results, with revenue recognized of $13.2 million, up from $7.6 million a year earlier. Net loss widened to $61.9 million from $53.9 million, though the loss per share improved to $0.30 from $0.32 as the weighted-average share count rose. The company said cash, cash equivalents, and marketable securities were $431.0 million at September 30, 2026, with a cash runway into the third quarter of 2028.
Key points
- Revenue recognized was $13.2 million in Q3 2026, versus $7.6 million in Q3 2025.
- Research and development expenses were $53.8 million and general and administrative expenses were $25.4 million in Q3 2026.
- Net loss was $61.9 million, or $0.30 per share, versus a net loss of $53.9 million, or $0.32 per share, a year earlier.
- Cash, cash equivalents, and marketable securities were $431.0 million at September 30, 2026, excluding a $12 million GSK milestone due in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.